BRCA1 and prostate cancer: S. et al. from 11 randomized controlled trials of PARPi in BRCA1/2-mutated populations, including ovarian, breast, pancreatic and prostate cancer, was performed to assess the efficacy difference of PARPi between BRCA1 and BRCA2 mutation carriers.